wugen

about

WUGEN Inc. is a biotechnology company developing a novel CAR-T therapy platform including an “off-the-shelf” fratricide-resistant CAR-T cell therapy for T-cell malignancies. 

wugen inc.

WUGEN’s state-of-the-art gene editing technologies and cutting-edge CAR-T cell therapy address some of the challenges that have limited the clinical development of allogeneic CAR-T cells. WUGEN was founded based on technology licensed from Washington University in St. Louis.